Navigating Preclinical Models and Medications for Peripheral Neuropathy: A Review

Area of Science:

• Neurology
• Pharmacology
• Toxicology

Background:

• Peripheral neuropathy (PN) involves nerve damage causing pain, weakness, and autonomic issues.
• Preclinical models are essential for understanding PN and developing new treatments.
• Current models vary in their ability to replicate human PN complexity.

Purpose of the Study:

• To review and evaluate preclinical models for peripheral neuropathy research.
• To assess the relevance of these models to human disease.
• To determine their utility in therapeutic development for PN.

Main Methods:

• Review of existing literature on various PN preclinical models.
• Analysis of Streptozotocin (STZ)-induced diabetic neuropathy models.
• Evaluation of chemotherapy-induced peripheral neuropathy (CIPN) models (Cisplatin, Paclitaxel).
• Assessment of surgical/trauma-induced nerve injury models.
• Review of drug efficacy studies (gabapentin, pregabalin, duloxetine, fluoxetine) in these models.

Main Results:

• STZ models have limitations in replicating diabetic neuropathy onset and progression.
• Cisplatin and Paclitaxel models are valuable for CIPN research but may not capture all deficits.
• Surgical/trauma models aid in understanding nerve regeneration.
• Several medications show therapeutic promise in preclinical settings.

Conclusions:

• No single preclinical model fully replicates human peripheral neuropathy.
• Each model offers unique insights into specific aspects of PN.
• Continued refinement and integrated approaches are vital for effective drug discovery and treatment optimization.